newsfilter
← Latest News
GlobeNewswire·

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene